Skip to main content

Clinical Trials › NCT04544436

Active, Not RecruitingPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Sponsored by Hoffmann-La Roche

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
864
Target enrollment
20
U.S. states
Nov 2020
Start date
Aug 2028
Expected completion

Interventions / Treatments

OcrelizumabAntihistamineMethylprednisolone

Conditions studied

Multiple Sclerosis

Where this trial is running (25 sites)

Alabama2 sites
Cullman · Homewood
California2 sites
Carlsbad · Stanford
Florida2 sites
Maitland · Tampa
Tennessee2 sites
Johnson City · Knoxville
Texas2 sites
Lubbock · San Antonio
Arizona1 site
Phoenix
Colorado1 site
Fort Collins
Indiana1 site
Avon
Kansas1 site
Kansas City
Louisiana1 site
Alexandria
Maine1 site
Scarborough
Wellesley
Michigan1 site
Detroit
Missouri1 site
St Louis
Nevada1 site
Las Vegas
New York1 site
Amherst
Ohio1 site
Dayton
Oklahoma1 site
Oklahoma City
Willow Grove
Kirkland

MS centers in Alabama

Compare treatment centers near a trial site by center type, providers and trials.

View Alabama centers

More Phase 3 trials

Browse all Phase 3 MS trials
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play